Ann Dermatol.  2022 Dec;34(6):419-430. 10.5021/ad.21.239.

Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea

Affiliations
  • 1Department of Dermatology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
  • 2Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 3Department of Dermatology, National Medical Center, Seoul, Korea
  • 4Department of Dermatology and Research Institute of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 5Department of Dermatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
  • 6Department of Dermatology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea
  • 7Department of Dermatology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
  • 8Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea
  • 9Department of Dermatology, Pusan National University Hospital, Busan, Korea
  • 10Department of Dermatology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea
  • 11Department of Dermatology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University, Yangsan, Korea
  • 12Department of Dermatology, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea
  • 13Department of Dermatology and Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
  • 14Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea
  • 15Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea
  • 16Department of Dermatology, Chosun University Hospital, College of Medicine, Chosun University, Gwangju, Korea
  • 17Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
  • 18Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea
  • 19Department of Dermatology, Wonkwang University Hospital, Iksan, Korea
  • 20Department of Dermatology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
  • 21Department of Dermatology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
  • 22Department of Dermatology, Chungnam National University Hospital, Daejeon, Korea
  • 23Department of Dermatology, Kyung Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, Korea
  • 24Medical Affairs, Sanofi-Aventis Korea Co., Ltd., Seoul, Korea
  • 25Department of Dermatology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Abstract

Background
Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited.
Objective
To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea.
Methods
Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured.
Results
Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt.
Conclusion
A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.

Keyword

Anxiety; Atopic dermatitis; Depression; Quality of life
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr